This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
CRL Stock to Gain From the Global Biotech Incubator Program Launch
by Zacks Equity Research
Charles River's new initiative specifically caters to early-stage biotechnology developers.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
by Zacks Equity Research
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
by Zacks Equity Research
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
by Zacks Equity Research
Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
by Zacks Equity Research
ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article.
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
by Zacks Equity Research
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
New Health Coaching Service on questhealth.com Set to Boost DGX Stock
by Zacks Equity Research
Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bruker Stock Might Rise From the Launch of Dimension Nexus AFM
by Zacks Equity Research
BRKR launches the Dimension Nexus AFM at the 2024 MRS Fall Meeting & Exhibit, expanding its Dimension AFM product line.
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
by Zacks Equity Research
Hologic upholds its focus on equity with new research findings on its Breast Imaging AI solution.
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
by Zacks Equity Research
PEN stays on investors' radars due to its robust portfolio expansion and international growth plans.
Reasons to Add Phibro Stock to Your Portfolio Right Now
by Zacks Equity Research
PAHC's Animal Health business, along with flourishing Mineral Nutrition and Performance Product businesses, sparks optimism for future growth.
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
by Zacks Equity Research
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.
Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues
by Zacks Equity Research
Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site
by Zacks Equity Research
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
by Zacks Equity Research
The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.
QGEN Stock Dips Despite Launch of Customized dPCR Assay Design Tools
by Zacks Equity Research
QIAGEN introduces two new customizable dPCR assay design tools featuring advanced design algorithms tailored for diverse microbial applications and custom NGS panels.
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
by Zacks Equity Research
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain?
by Zacks Equity Research
HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI.
New Alliances to Support STERIS Stock Despite Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.